N-acetyl-cysteine
(Die Seite wurde neu angelegt: „{{up|PHA ImmunoNutrients}} {{tp|p=32344315|t=2020. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome |p…“)
Aktuelle Version vom 12. April 2021, 18:15 Uhr
| PHA ImmunoNutrients |
32344315 2020. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome
32345063 2020. Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic
32503814 2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
32504923 2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
C7301821 2020. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population consider N-acetylcysteine as early therapeutic intervention.
32662664 2020. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.
32707089 2020. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine.
32780893 2020. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.
32828741 2020. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.
32837898 2020. The effects of N-acetyl cysteine on acute viral respiratory infections in humans: A rapid review.
32964918 2020. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19.
33080692 2020. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report.
33109047 2020. Perspectives for the use of N-acetylcysteine as a candidate drug to treat COVID-19.
33177829 2020. N-Acetylcysteine to Combat COVID-19: An Evidence Review.
